Partially enhanced selectivity for Btk was shown in kinase assays for the irreversible Btk inhibitor evobrutinib,25, 26 and thus far no bleeding events have been reported in its currently ongoing trials in patients with multiple sclerosis.27, 28. This evidence concerns the gene BTK and multiple sclerosis.